文献速递质量管理与危急值临床生化

并非所有偏倚都等同:如何处理实验室测量中的偏倚

Not all biases are created equal: how to deal with bias on laboratory measurements.
PubMed 文献 · Clin Chem Lab Med · 2024-11-26

本文讨论在计量溯源理论引入检验医学后,偏倚定义与管理的变化。实验室应依赖制造商确保体外诊断医疗器械(IVD-MD)溯源至最高参考物质,并在上市前校准品正确度转移中校正偏倚。若溯源实施中校正不足,可通过基于溯源的室间质评发现,并用验证实验确认,偏倚显著性应基于其对测量不确定度(MU)的影响评估。

要点

  • IVD-MD上市前应由制造商确保溯源并校正偏倚。
  • 溯源实施中校正不足的偏倚可由基于溯源的室间质评发现。
  • 偏倚显著性应基于其对测量不确定度的影响评估。

核心结论

  • IVD-MD应溯源至最高参考物质并在上市前校正偏倚,校正不足的偏倚需基于测量不确定度评估其显著性并处理。

主要发现

  • 溯源实施中校正不足可导致偏倚,该偏倚可由基于溯源的室间质评发现并经验证实验确认。
  • 常规使用中重校准和批号更换可引起随机发生的偏倚,通过内部质量控制纳入中间再现性估计。

关键数值与推荐

  • 偏倚显著性应基于其对测量不确定度的影响评估。
  • 随机发生的偏倚可耐受至临床样本的估计测量不确定度满足预定规格。

临床怎么用

  • IVD制造商被警告后应立即调查并采取纠正措施修复问题。
  • 终用户应重新调整IVD-MD以校正变得显著的偏倚,若偏倚仍存在应要求制造商整改。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Although the concept of bias appears consolidated in laboratory science, some important changes in its definition and management have occurred since the introduction of metrological traceability theory in laboratory medicine. In the traceability era, medical laboratories should rely on manufacturers who must ensure traceability of their in vitro diagnostic medical devices (IVD-MD) to the highest available references, providing bias correction during the trueness transfer process to calibrators before they are marketed. However, sometimes some bias can be observed arising from an insufficient correction during the traceability implementation. This source of bias can be discovered by the IVD-MD surveillance by traceability-based external quality assessment and confirmed by ad-hoc validation experiments. The assessment of significance should be based on its impact on measurement uncertainty (MU) of results. The IVD manufacturer, appropriately warned, is responsible to take an immediate investigation and eventually fix the problem with a corrective action. Even if IVD-MD is correctly aligned in the validation steps and bias components are eliminated, during ordinary use the system may undergo systematic variations such as those caused by recalibrations and lot changes. These sources of randomly occurring bias are incorporated in the estimate of intermediate reproducibility of IVD-MD through internal quality control and can be tolerated until the estimated MU on clinical samples fulfils the predefined specifications. A readjustment of the IVD-MD by the end-user must be undertaken to try to correct the bias becoming significant. If the bias remains, the IVD manufacturer should be requested to rectify the problem.

来源:Clin Chem Lab Med,查看原文。版权归原作者所有。

引用

  1. Panteghini M. Not all biases are created equal: how to deal with bias on laboratory measurements. Clin Chem Lab Med. 2024. PMID: 39585762. doi:10.1515/cclm-2024-1208

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。